ArticleMiddle East African journal of ophthalmology2012
Diabetic macular edema: current and emerging therapies.
Article in Middle East African journal of ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.Advances in therapy · 2023Pooled it
- CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.Retina (Philadelphia, Pa.) · 2018Trial
- Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema.Indian journal of ophthalmology · 2018Trial
- A randomized clinical trial comparing fixed vs pro-re-nata dosing of Ozurdex in refractory diabetic macular oedema (OZDRY study).Eye (London, England) · 2015Trial
- Expanding Arsenal against Ocular Diseases through Nanoemulsion: Success So Far and the Road Ahead.Current drug delivery · 2025Review
- Serum Apolipoprotein B and B/A1 Ratio as Early Negative Biomarkers for OCT- and OCTA-Detected Retinal Changes in Diabetic Macular Edema.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- The Impact of the Foveal Bulge on Visual Acuity in Resolved Diabetic Macular Edema and Retinal Vein Occlusions.Cureus · 2024Article
- Cost-Effectiveness of Faricimab in the Treatment of Diabetic Macular Oedema (DMO): A UK Analysis.PharmacoEconomics - open · 2024Article
- Recommendations for diabetic macular edema management by retina specialists and large language model-based artificial intelligence platforms.International journal of retina and vitreous · 2024Article
- Article
- Treatment patterns and persistence rates with anti-vascular endothelial growth factor treatment for diabetic macular oedema in the UK: A real-world study.Diabetic medicine : a journal of the British Diabetic Association · 2022Article
- Severity of diabetic retinopathy and its relationship with age at onset of diabetes mellitus in India: A multicentric study.Indian journal of ophthalmology · 2021Article
- Diabetic macular edema treatment guidelines in India: All India Ophthalmological Society Diabetic Retinopathy Task Force and Vitreoretinal Society of India consensus statement.Indian journal of ophthalmology · 2021Article
- Significance of monitoring vascular endothelial growth factor, monocyte chemoattractant protein-1 and Interleukin-8 in diabetic macular edema towards early identification of nonresponders to ranibizumab therapy.Indian journal of ophthalmology · 2021Article
- Article
- Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice.BMJ open ophthalmology · 2021Article
- The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema.Ophthalmology and therapy · 2019Article
- Rethinking Nuclear Receptors as Potential Therapeutic Targets for Retinal Diseases.Journal of biomolecular screening · 2016Review
- Novel Therapies in Development for Diabetic Macular Edema.Current diabetes reports · 2015Review
- Nanoengineering of therapeutics for retinal vascular disease.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic macular edema is a leading cause of vision impairment among people within the working- age population. This review discusses the pathogenesis of diabetic macular edema and the treatment options currently available for the treatment of diabetic macular edema, including for focal/grid photocoagulation, intravitreal corticosteroids and intravitreal anti-vascular endothelial growth factor agents. The biologic rationale for novel therapeutic agents, many of which are currently being evaluated in clinical trials, also is reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.